India Patent Appeals Court Rules For Cipla In Fight Over Pfizer's Sutent
This article was originally published in PharmAsia News
Executive Summary
Pfizer lost another round with Cipla when India's Intellectual Property Appellate Board rejected the U.S. drug maker's appeal of a ruling against its patent on Sutent (sunitinib) for treating liver and kidney cancer.